Audentes Therapeutics, Inc. (NASDAQ:BOLD) major shareholder Orbimed Advisors Llc sold 672,000 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $28.25, for a total transaction of $18,984,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Orbimed Advisors Llc also recently made the following trade(s):

  • On Thursday, September 7th, Orbimed Advisors Llc sold 5,000 shares of Audentes Therapeutics stock. The shares were sold at an average price of $22.35, for a total value of $111,750.00.

Shares of Audentes Therapeutics, Inc. (NASDAQ BOLD) opened at 28.01 on Monday. The stock’s market cap is $778.23 million. Audentes Therapeutics, Inc. has a 12-month low of $13.13 and a 12-month high of $33.43. The company has a 50 day moving average price of $24.77 and a 200 day moving average price of $24.77.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.10). Analysts anticipate that Audentes Therapeutics, Inc. will post ($3.50) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Insider Selling: Audentes Therapeutics, Inc. (BOLD) Major Shareholder Sells $18,984,000.00 in Stock” was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.watchlistnews.com/insider-selling-audentes-therapeutics-inc-bold-major-shareholder-sells-18984000-00-in-stock/1602125.html.

BOLD has been the topic of a number of research analyst reports. Bank of America Corporation restated a “buy” rating and issued a $33.00 target price (up previously from $23.00) on shares of Audentes Therapeutics in a research report on Friday, September 22nd. ValuEngine upgraded shares of Audentes Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 24th. Evercore ISI initiated coverage on shares of Audentes Therapeutics in a research note on Wednesday, August 16th. They set an “outperform” rating and a $23.00 target price for the company. Finally, Zacks Investment Research cut shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Audentes Therapeutics has an average rating of “Buy” and a consensus target price of $24.17.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Redmile Group LLC increased its position in Audentes Therapeutics by 77.8% during the 2nd quarter. Redmile Group LLC now owns 1,459,616 shares of the biotechnology company’s stock worth $27,922,000 after purchasing an additional 638,780 shares in the last quarter. Jennison Associates LLC raised its holdings in Audentes Therapeutics by 182.4% in the second quarter. Jennison Associates LLC now owns 846,273 shares of the biotechnology company’s stock valued at $16,189,000 after buying an additional 546,617 shares during the period. Vanguard Group Inc. raised its holdings in Audentes Therapeutics by 130.3% in the second quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock valued at $12,978,000 after buying an additional 383,837 shares during the period. State Street Corp raised its holdings in Audentes Therapeutics by 231.6% in the second quarter. State Street Corp now owns 221,276 shares of the biotechnology company’s stock valued at $4,234,000 after buying an additional 154,544 shares during the period. Finally, Alliancebernstein L.P. lifted its position in Audentes Therapeutics by 31.5% during the second quarter. Alliancebernstein L.P. now owns 640,654 shares of the biotechnology company’s stock valued at $12,256,000 after buying an additional 153,617 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Insider Buying and Selling by Quarter for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.